Recently Ethex Corporation, a Missouri company, announced the recall of morphine sulfate tablets due to reports that some may have been produced with double the thickness and double the active ingredient. The company, which initially identified 60 mg extended release tablets only, has now expanded the recall to include 30 mg morphine sulfate tablets. Distribution of this medication, described as a white or pink oval tablet with “60” or “30” on one side and “E” on the other, would have been in April of 2008, according to the company. This can be a very dangerous situation, as overdosing on morphine can be fatal. Serious side effects can also include respiratory problems, including low blood pressure, difficulty breathing, or the inability to breathe.
This marks the second recall in less than two months of tablets produced with twice the thickness and twice the active ingredient. In our June report, we wrote about Digitek tablets, manufactured by Actavis Totowa, which were recalled for the same reason. Digitek defective tablets can cause serious, life-threatening events and have been categorized by the FDA as a Class I recall, the most serious classification. Chad Cook is the lead lawyer at our firm investigating cases where patients have been seriously injured from either Ethex morphine sulfate tablets or Digitek tablets.
The maker of Digitek faces at least nine federal lawsuits in New Jersey, including one where a patient died, alleging the drug was dangerous and defective. The lawsuits are pending in U.S. District Court in Newark. On April 25th Actavis Totowa started a nationwide recall of all strengths of the Digitek pills, which are distributed by Mylan Pharmaceuticals Inc. and UDL Laboratories Inc. Similar lawsuits have been filed in Alabama, West Virginia and California. Ted Meadows from our firm is also evaluating Digitek cases for our firm. He can be contacted at 800-898-2034.
Source: Associated Press
Contact us today for a free legal consultation with an experienced attorney.
Fields marked *may be required for submission.
If you would like to subscribe to the Jere Beasley Report digital edition, simply visit our Subscriptions page and provide the necessary information or call us at 800-898-2034.
Attorney Advertising - Prior results do not guarantee a similar outcome.